Collaborations

BIONOR PHARMA, Oslo, Norway. 

  • Acting Chief Medical Officer [CMO].
  • Therapeutic Vaccines’ Clinical Development & Strategy.
  • Design of pivotal global study.
  • Medical Affairs.
  • [2014-2017]

Da Volterra, Paris, France. 

  • Executive Consultants to CEO & Team.
  • Drug development strategy countering Antibiotic Resistance
  • [2012].

ENANTA Pharmaceuticals, Watertown MA, USA.

Exl Pharma. New York, NY, USA. 

  • Professional Educational Courses on Medical & Scientific Affairs.

GENZYME Corporation, Cambridge MA, USA.

  • Medical Consultant, Pharmacovigilance Dept.
  • [2012].

GSK/ViiV Healthcare, RTP NC, USA.

  • A global specialist HIV company established by GlaxoSmithKline, Pfizer and Shinogi.
  • [2012 – 2013].

INNAVIRVAX, Genopole™ Biotechnology Hub, Evry, France. 

  • Acting Chief Medical Officer [CMO]
  • Acting Head of Translational Medicine
  • Design and Clinical Operations for pivotal International study
  • [2011-2014]

METYS Pharmaceuticals, Basel, Switzerland.

NOVOBIOPHARMA Delaware, USA [LLC was Co-Founder].

  • Building Sustainable Alliances to Provide Innovative Business & Science Solution
  • [2013-2016]

NOVARTIS, East Hannover, New Jersey, USA & Basel, Switzerland

  • Medical Affairs [Medical Education, Publications, Phase IV].

ORCHARD Therapeutics, London, UK.

  • Gene Therapy in Orphan Diseases

STALLERGENES GREER, Antony, France & Boston MA, USA.

  • Acting Global Head of Clinical Development & Medical Affairs
  • Global Medical Affairs coverage: Asia Pacific – Canada – Europe (East/West) – USA.
  • Clinical Development: Pivotal phase III clinical study:
    1,600 patients from 13 countries with 231 participating investigative sites,
    largest study of its kind in the therapeutic area [www.stallergenesgreer.com].

TRANSGENE, Strasbourg, France & Cambridge MA, USA.

  • Therapeutic Vaccine Clinical Trial.

VERSANTIS ETH, Zurich, Switzerland.